Meet the Judges
Meet the Judges
The Judging panel includes experts and senior representatives from the University of Glasgow, BBC, GlaxoSmithKline, Sistemic, and AstraZeneca. Read more to find out about the Judges...
Prof Dame Anna F Dominiczak
Professor Dame Anna Dominiczak DBE, MD, FRCP, FAHA, FRSE, FMedSci
Professor Dame Anna Dominiczak is Regius Professor of Medicine, Vice Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow as well as honorary consultant physician and non-executive member of NHS Greater Glasgow and Clyde Health Board. In 2016, she was awarded a DBE for services to cardiovascular and medical science.
Professor Dominiczak is one of the world’s leading cardiovascular scientists and clinical academics. She held a British Heart Foundation Chair of Cardiovascular Medicine at the University of Glasgow between 1997 and 2010, and directorship of the Cardiovascular Research Centre between 2000 and 2010. Her major research interests are in hypertension, cardiovascular genomics and precision medicine, where she not only publishes extensively in top peer-reviewed journals (over 400 publications), but also excels in large-scale research funding for programmes and infrastructure (with a total value in excess of £100M over the last seven years). She leads a collaboration of four universities, four academic NHS Health Boards across Scotland and two major industry partners in a public/private partnership focused on precision medicine, with a value in excess of £20M.
Professor Dominiczak is a Fellow of the Royal College of Physicians, the American Heart Association, the Academy of Medical Sciences, the Royal Society of Edinburgh, the European Society of Cardiology and the Society of Biology. She is a member of the British Medical Association, British Hypertension Society, European Society of Hypertension, International Society of Hypertension, British Endocrine Society, Association of Physicians of Great Britain and Ireland, American Physiological Society, British Atherosclerosis Society, British Cardiovascular Society and European Atherosclerosis Society. From 2013 to 2015, she was President of the European Society of Hypertension.
Since 2012, she has been Editor-in-Chief of Hypertension, journal of the American Heart Association and the world’s top journal in her area of research.
Dr Carol Clugston
Dr Carol Clugston took up the post of Chief Operating Officer of the College of Medical, Veterinary and Life Sciences in August 2010. MVLS is the largest of four Colleges in the University of Glasgow, with over 2,200 staff and an annual turnover exceeding £230M. As Chief Operating Officer, she works in partnership with the Head of College in strategic planning, budgeting and implementation of complex multi-partner strategic projects, and has responsibility for 750 professional services staff supporting the College's three Schools and seven Research Institutes. She also leads the College's Research Impact Strategy, which resulted in the University of Glasgow being awarded “Top University” in the BBSRC’s three-year Excellence with Impact competition.
Most recently, Dr Clugston played a major role in the planning, funding and development of the academic capital infrastructure projects at the Queen Elizabeth University Hospital (QEUH), now the largest hospital in Western Europe. With the Head of College, she has driven the “triple helix” partnership with industry and the NHS to add value to healthcare through innovation. This has included developing over £100M infrastructure with a focus on precision medicine, including the 22,000 sq ft Clinical Innovation Zone for industry, Clinical Research Facilities for clinical trials, and Imaging Centre of Excellence (“ICE”) incorporating Scotland’s first 7 Tesla MRI scanner. The ICE facility is partly funded by Glasgow City Region City Deal, and is stimulating economic growth through the development of a life sciences cluster at QEUH. Dr Clugston also played a key role in the development of the £20M Stratified Medicine Scotland Innovation Centre, now located within the Clinical Innovation Zone, and is a Board member. Other externally facing roles include Lay Advisor of the Royal College of Physicians of Edinburgh and Trustee of Glasgow Science Centre.
Dr Clugston was awarded the prestigious Lord Provost's Award from the City of Glasgow in 2017 in the category of health, in recognition of the major role she played at the new Queen Elizabeth University Hospital. She is also the 2018 recipient of the 30% Club Scholarship to the London Business School’s Senior Executive Programme.
Dr Harper VanSteenhouse
Harper VanSteenhouse, PhD, is General Manager and Founder of BioClavis, LTD. Harper has extensive experience in both product commercialization and development/management, with a focus on strategic, financial, marketing and operations leadership. He is formally trained in cell and molecular developmental biology with a PhD in Neuroscience from University of California, San Diego. Dr. VanSteenhouse has over a decade of experience in commercialization and marketing of a variety of life science products and technologies. As Director of Technical Integration at BioSpyder, Harper joined the growing company to lead commercialization (sales, marketing, and business development) and ultimately the initiative to spin out BioClavis as a diagnostics company in Europe. At Illumina, he was involved in a number of corporate marketing projects including web, outbound and events. Then, held management responsibilities for a line of array products for structural variation detection, and led development of a diagnostic microarray for detection of chromosomal abnormalities in children. In a leadership role in the diagnostics product marketing group, he managed a broad portfolio of products under development as diagnostic applications of next-generation sequencing. At BioNano Genomics, he built and led marketing and commercialization efforts for the definition and launch of the new company brand, product development, and commercial rollout of products based on single-molecule imaging. At Fluidigm, he led field marketing and sales training and support, responsible for their entire product portfolio of single-cell, genomic and proteomic instrumentation and consumables.
Mr Melville Anderson
Manages the IP & Commercialisation function within the Research Strategy & Innovation Office (RSIO) at the University of Glasgow. The function provides support to the University on the protection and exploitation of IP assets. Mel has significant experience in working with inventors, entrepreneurs and investors to incubate, fund and grow new ventures. He offers teams support and mentoring with regard to intellectual property, market opportunity validation, business development, business planning, company formation and investor readiness.